Novavax is prepared to deliver protein-based non-mRNA JN.1 COVID-19 vaccine in line with WHO recommendation this fall.
Novavax is Prepared to Deliver Protein-based Non-mRNA JN.1 COVID-19 Vaccine in Line with WHO Recommendation this Fall
The World Health Organization’s (WHO) Technical Advisory Group on COVID-19 Vaccine Composition recommended the use of a monovalent JN.1 lineage COVID-19 vaccine as one approach to address the ongoing SARS-CoV-2 virus evolution, which is expected to lead to circulation of additional JN.1 descendant strains. Novavax plans to be ready to deliver our JN.1 protein-based non-mRNA COVID-19 vaccine globally this fall. We have been developing and manufacturing this vaccine candidate at risk and are well positioned for the upcoming vaccination season.
Our most recent nonclinical data have demonstrated that our JN.1 vaccine candidate induces neutralization responses to JN.1, JN.4, JN.1.11.1, JN.1.7, JN.1.13.1 and JN.1.16 strains. Our JN.1 vaccine candidate also produces polyfunctional cellular CD4+ T cell responses to a range of omicron strains including JN.1 and JN.1.11. These responses indicate once again that our vaccine technology can induce broadly neutralizing responses against multiple variant strains, including circulating forward drift variants.
Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) has not been approved or licensed by FDA, but has been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins